Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

India rejects Abbott's patent application for Kaletra

This article was originally published in Scrip

Executive Summary

India has rejected Abbott's patent application for its antiretroviral drug, Kaletra/Aluvia (lopinavir plus ritonavir), following opposition from the US-based non-profit group, Initiative for Medicines, Access and Knowledge (I-MAK), as well as Cipla, Matrix Laboratories (now part of Mylan) and the private Indian firm, Okasa.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register